Ligand Pharmaceuticals Files For Mixed-Securities Shelf Offering, Size Not Disclosed

-Reuters

-Reuters

Total
0
Shares
Related Posts
Read More

IPA Responds To 13D Filing By Ingalls & Snyder, LLC; IPA Announced That It Has Recently Begun Interviewing Potential Candidates To Refresh Its Board Of Directors In Its Search For The Optimal Board Composition

IPA responds to 13D Filing by Ingalls & Snyder, LLCIPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, today issued the following

IPA